Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.66
(
-1.98%
)
Bitcoin
74,212.23
(
0.36%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 58003

Tuesday, 01/13/2009 4:58:38 AM

Tuesday, January 13, 2009 4:58:38 AM

Post# of 257253
VRTX made two announcements Monday re Telaprevir:

1. ILLUMINATE, the smaller of the two phase-3 trials in treatment-naïve HCV, is now fully enrolled (ADVANCE, the larger phase-3 trial, was fully enrolled in Oct 2008.)

2. Japanese partner, Mitsubishi Tanabe, started a phase-3 trial for 300 genotype-1 patients that includes both the first– and second-line settings. Results are expected in mid 2011.

http://finance.yahoo.com/news/Vertex-Outlines-2009-Business-bw-14027760.html


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now